Targeted therapies : bevacizumab—has it reached its final resting place?
Kerr, David J. and Young, Annie M. (2011) Targeted therapies : bevacizumab—has it reached its final resting place? Nature Reviews Clinical Oncology, Vol.8 (No.4). pp. 195-196. ISSN 1759-4774Full text not available from this repository.
Official URL: http://dx.doi.org/10.1038/nrclinonc.2011.32
We all recognize the cycle of hyperbole, hopelessness and habituation that many therapeutic agents follow and it would seem that bevacizumab has almost reached its final resting place, at least with respect to its usage in the adjuvant setting for the treatment of colon cancer. A range of phase III trials indicate that bevacizumab has variable clinical activity in advanced-stage disease,1 but this has not been reproduced in the adjuvant setting.
|Item Type:||Journal Item|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Journal or Publication Title:||Nature Reviews Clinical Oncology|
|Publisher:||Nature Publishing Group|
|Official Date:||April 2011|
|Page Range:||pp. 195-196|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)